Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine by Zay Yar Oo, Martina Proctor, Alexander J. Stevenson, Deborah Nazareth, Madushan Fernando, Sheena M. Daignault, Catherine Lanagan, Sebastian Walpole, Vanessa Bonazzi, Dubravka Škalamera, Cameron Snell, Nikolas K. Haass, Jill E. Larsen, Brian Gabrielli

Get full text